Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vincerx Pharma, Inc. (VINC)
USD0.01
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
260 Sheridan Avenue 94306
Palo Alto, CA, US
Palo Alto, CA, US
CEO
Raquel E. Izumi
Website
vincerx.com
IPO
2020-05-27
CIK 1796129 ISIN US92731L3042
Also trades on
NASDAQ Global Select · VINCU (USD)
NASDAQ Global Select · VINCW (USD)
Other OTC · VINC (USD)
Description
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.01
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5.1K
Beta
1.45
Float Shares
4.75M
Free Float %
90.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -2.31% | +5.83% | -2.31% | -74.60% | -99.97% | -100.00% | -99.99% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
0.01
Low
2.00
+15,648.0%
Consensus
3.00
+23,522.0%
Median
3.00
+23,522.0%
High
4.00
+31,396.1%
DCF (Unlevered)
0.78
+6,063.2%
DCF (Levered)
0.95
+7,402.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-06 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
3.00
+23,522.0%
|
Quality scores
Altman Z-Score
-76.48
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+15.9% Q1'25: +54.5% (vs Q1'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'25: +562.5% (vs Q1'24)
-
Share dilution Biotechnology: -3.4%-10.9% ★ Q1'25: -11.3% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'25: 0.00× (vs Q1'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
—
|
17.57M
est.
|
220.0K
220.0K – 220.0K
-98.7% YoY
|
4.14M
4.14M – 4.14M
+1,781.8% YoY
|
17.45M
17.45M – 17.45M
+321.5% YoY
|
| EBITDA |
-31.46M
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
—
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-30.07M
est: -81.65M (+63.2%)
|
-62.81M
est.
|
-59.67M
-59.67M – -59.67M
+5.0% YoY
|
-58.62M
-58.62M – -58.62M
+1.8% YoY
|
-55.48M
-55.48M – -55.48M
+5.4% YoY
|
| SGA |
15.98M
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-5.75
est: -15.60 (+63.1%)
|
-12.00
est.
|
-11.40
-11.40 – -11.40
+5.0% YoY
|
-11.20
-11.20 – -11.20
+1.8% YoY
|
-10.60
-10.60 – -10.60
+5.4% YoY
|
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 2.99M | 9.99% | — | 2.99M | — | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 2 | Steven Boyd | 2.99M | 9.99% | — | 2.99M | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 3 | Prosight Management, LP | 2.50M | 9.10% | — | 2.50M | — | 2.50M | IA | Delaware | 2024-05-03 | ↗ |
| 4 | Prosight Partners, LLC | 2.50M | 9.10% | — | 2.50M | — | 2.50M | OO | Delaware | 2024-05-03 | ↗ |
| 5 | W. Lawrence Hawkins | 2.50M | 9.10% | — | 2.50M | — | 2.50M | HC, IN | Delaware | 2024-05-03 | ↗ |
| 6 | David Rosen | 2.11M | 10.01% | — | 2.11M | — | — | IN | United States of America | 2022-02-10 | ↗ |
| 7 | Rubric Capital Management LP | 2.11M | 10.01% | — | 2.11M | — | — | IA, PN | State of Delaware | 2022-02-10 | ↗ |
| 8 | GOLDMAN SACHS & CO. LLC | 2.08M | 9.80% | — | 13.00 | — | 2.08M | BD, IA, OO | Delaware | 2023-02-08 | ↗ |
| 9 | THE GOLDMAN SACHS GROUP, INC. | 2.08M | 9.80% | — | 13.00 | — | 2.08M | HC, CO | Delaware | 2023-02-08 | ↗ |
| 10 | Andrew McDonald | 1.62M | 11.60% | — | 1.62M | — | 1.62M | IN | United States | 2021-01-04 | ↗ |
| 11 | Jonas Grossman | 1.62M | 11.60% | — | 1.62M | — | 1.62M | IN | United States | 2021-01-04 | ↗ |
| 12 | LifeSci Investments, LLC | 1.62M | 11.60% | 1.62M | — | 1.62M | — | OO | United States | 2021-01-04 | ↗ |
| 13 | 46-2772035 | 1.41M | 6.70% | — | 1.41M | — | 1.41M | IA | DELAWARE, USA | 2023-02-14 | ↗ |
| 14 | JOHN B. HELMERS | 1.41M | 6.70% | — | 1.41M | — | 1.41M | IN | USA | 2023-02-14 | ↗ |
| 15 | Company, L.P. | 1.38M | 6.56% | — | 1.38M | — | — | PN | Delaware | 2021-09-28 | ↗ |
| 16 | Deerfield Mgmt, L.P. | 1.38M | 6.56% | — | 1.38M | — | — | PN | Delaware | 2021-09-28 | ↗ |
| 17 | Deerfield Partners, L.P. | 1.38M | 6.56% | — | 1.38M | — | — | PN | Delaware | 2021-09-28 | ↗ |
| 18 | James E. Flynn | 1.38M | 6.56% | — | 1.38M | — | — | IN | United States | 2021-09-28 | ↗ |
| 19 | S | 1.14M | 5.39% | — | 1.14M | — | 1.14M | PN | Delaware | 2022-02-11 | ↗ |
| 20 | BANK OF AMERICA CORPORATION56-0906609 | 1.08M | 5.10% | — | 1.08M | — | 1.08M | HC | — | 2024-02-13 | ↗ |
| 21 | 47-3021161 | 869.6K | 4.10% | — | 869.6K | — | 869.6K | OO | DELAWARE, USA | 2023-02-14 | ↗ |
| 22 | A. GLENN HELMERS | 869.6K | 4.10% | — | 869.6K | — | 869.6K | IN | USA | 2023-02-14 | ↗ |
| 23 | RTW Investments, LP | 750.0K | 5.36% | — | 750.0K | — | 750.0K | IA, PN, OO | Delaware United States America | 2021-02-16 | ↗ |
| 24 | Roderick Wong | 750.0K | 5.36% | — | 750.0K | — | 750.0K | HC, IN | Delaware United States America | 2021-02-16 | ↗ |
| 25 | Prosight Plus Fund, LP | 671.2K | 2.40% | — | 671.2K | — | 671.2K | PN | Delaware | 2024-05-03 | ↗ |
| 26 | Michael Rice | 616.9K | 11.60% | — | 1.62M | — | 616.9K | IN | United States | 2021-01-04 | ↗ |
| 27 | TANG CAPITAL MANAGEMENT, LLC | 500.0K | 6.70% | — | 500.0K | — | 500.0K | — | DELAWARE | 2020-03-16 | ↗ |
| 28 | Prosight Fund, LP | 213.4K | 0.80% | — | 213.4K | — | 213.4K | PN | Delaware | 2024-05-03 | ↗ |
| 29 | 85-3527027 | — | 0.00% | — | — | — | — | — | Menlo Park, California | 2021-08-04 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.09
Neutral
Ratio by volume
1.20
Neutral
Buys
24
Sells
22
Shares acquired
2.00M
Shares disposed
1.67M
Cash buys
—
Cash sales
—
Net activity
+337,996
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-20 | Haas Kevin | Officer | — | — | Common Stock | 0 | 0.00 | — | 42,776 | D | ↗ |
| 2024-08-12 | THOMAS TOM C | Officer | D-Return | D | Stock Option (right to buy) | 31,250 | 7.38 | 230.6K | 0 | — | ↗ |
| 2024-08-12 | Seelenberger Alexander A. | Officer | D-Return | D | Stock Option (right to buy) | 86,000 | 1.17 | 100.6K | 0 | — | ↗ |
| 2024-08-12 | Izumi Raquel E. | Director / Officer | A-Award | A | Stock Option (right to buy) | 41,250 | 0.55 | 22.7K | 165,000 | — | ↗ |
| 2024-08-12 | Hamdy Ahmed MD | Director / Officer | D-Return | D | Stock Option (right to buy) | 127,500 | 6.26 | 798.2K | 0 | — | ↗ |
| 2024-05-23 | THOMAS TOM C | Officer | A-Award | A | Stock Option (right to buy) | 31,250 | 7.38 | 230.6K | 125,000 | — | ↗ |
| 2024-05-23 | Stevens Ruth E. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.70 | 10.6K | 15,000 | — | ↗ |
| 2024-05-23 | Seelenberger Alexander A. | Officer | A-Award | A | Stock Option (right to buy) | 31,250 | 7.38 | 230.6K | 125,000 | — | ↗ |
| 2024-05-23 | Salva Francisco D. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.70 | 10.6K | 15,000 | — | ↗ |
| 2024-05-23 | Lee John H. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.70 | 10.6K | 15,000 | — | ↗ |
| 2024-05-23 | Izumi Raquel E. | Director / Officer | A-Award | A | Stock Option (right to buy) | 41,250 | 7.38 | 304.4K | 165,000 | — | ↗ |
| 2024-05-23 | Hamdy Ahmed MD | Director / Officer | A-Award | A | Stock Option (right to buy) | 53,254 | 7.38 | 393.0K | 200,000 | — | ↗ |
| 2024-05-23 | Druker Brian | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.70 | 10.6K | 15,000 | — | ↗ |
| 2024-05-23 | Bushnell Laura I. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.70 | 10.6K | 15,000 | — | ↗ |
| 2024-03-07 | THOMAS TOM C | Officer | A-Award | A | Stock Option (right to buy) | 93,750 | 7.38 | 691.9K | 93,750 | — | ↗ |
| 2024-03-07 | Seelenberger Alexander A. | Officer | A-Award | A | Stock Option (right to buy) | 93,750 | 7.38 | 691.9K | 93,750 | — | ↗ |
| 2024-03-07 | Izumi Raquel E. | Director / Officer | A-Award | A | Stock Option (right to buy) | 123,750 | 7.38 | 913.3K | 123,750 | — | ↗ |
| 2024-03-07 | Hamdy Ahmed MD | Director / Officer | A-Award | A | Stock Option (right to buy) | 146,746 | 7.38 | 1.08M | 146,746 | — | ↗ |
| 2023-08-11 | Seelenberger Alexander A. | Officer | P-Purchase | A | Common Stock | 10,500 | 0.95 | 10.0K | 30,280 | — | ↗ |
| 2023-08-10 | THOMAS TOM C | Officer | P-Purchase | A | Common Stock | 5,000 | 0.95 | 4.8K | 219,935 | — | ↗ |
| 2023-08-10 | Izumi Raquel E. | Director / Officer | P-Purchase | A | Common Stock | 3,440 | 0.93 | 3.2K | 85,214 | — | ↗ |
| 2023-08-10 | Hamdy Ahmed MD | Director / Officer | P-Purchase | A | Common Stock | 5,400 | 0.96 | 5.2K | 96,060 | — | ↗ |
| 2023-08-09 | Izumi Raquel E. | Director / Officer | P-Purchase | A | Common Stock | 13,036 | 0.90 | 11.7K | 81,774 | — | ↗ |
| 2023-08-09 | Hamdy Ahmed MD | Director / Officer | P-Purchase | A | Common Stock | 16,900 | 0.95 | 16.0K | 90,660 | — | ↗ |
| 2023-05-25 | Stevens Ruth E. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.62 | 24.3K | 15,000 | — | ↗ |
| 2023-05-25 | Salva Francisco D. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.62 | 24.3K | 15,000 | — | ↗ |
| 2023-05-25 | Lee John H. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.62 | 24.3K | 15,000 | — | ↗ |
| 2023-05-25 | Druker Brian | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.62 | 24.3K | 15,000 | — | ↗ |
| 2023-05-25 | Bushnell Laura I. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.62 | 24.3K | 15,000 | — | ↗ |
| 2023-02-15 | THOMAS TOM C | Officer | A-Award | A | Stock Option (right to buy) | 86,000 | 1.17 | 100.6K | 86,000 | — | ↗ |
| 2023-02-15 | Seelenberger Alexander A. | Officer | A-Award | A | Stock Option (right to buy) | 86,000 | 1.17 | 100.6K | 86,000 | — | ↗ |
| 2023-02-15 | Izumi Raquel E. | Director / Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 1.17 | 105.3K | 90,000 | — | ↗ |
| 2023-02-15 | Hamdy Ahmed MD | Director / Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 1.17 | 105.3K | 90,000 | — | ↗ |
| 2022-12-14 | THOMAS TOM C | Officer | P-Purchase | A | Common Stock | 7,000 | 0.83 | 5.8K | 10,000 | — | ↗ |
| 2022-12-14 | Izumi Raquel E. | Officer | P-Purchase | A | Common Stock | 28,738 | 0.88 | 25.4K | 68,738 | — | ↗ |
| 2022-12-14 | Hamdy Ahmed MD | Officer | P-Purchase | A | Common Stock | 35,280 | 0.87 | 30.5K | 73,760 | — | ↗ |
| 2022-11-15 | THOMAS TOM C | Officer | A-Award | A | Stock Option (right to buy) | 56,000 | 0.00 | — | 56,000 | — | ↗ |
| 2022-11-15 | Seelenberger Alexander A. | Officer | A-Award | A | Stock Option (right to buy) | 56,000 | 0.00 | — | 56,000 | — | ↗ |
| 2022-11-15 | Izumi Raquel E. | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-11-15 | Hamdy Ahmed MD | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-08-25 | THOMAS TOM C | Officer | A-Award | A | Stock Option (right to buy) | 58,000 | 0.00 | — | 58,000 | — | ↗ |
| 2022-08-25 | Seelenberger Alexander A. | Officer | A-Award | A | Stock Option (right to buy) | 58,000 | 1.71 | 99.2K | 58,000 | — | ↗ |
| 2022-08-25 | LOWE CHRISTOPHER P. | Director | P-Purchase | A | Common Stock | 11,600 | 1.65 | 19.1K | 40,000 | — | ↗ |
| 2022-08-25 | Izumi Raquel E. | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-08-25 | Hamdy Ahmed MD | Director / Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 1.71 | 102.6K | 60,000 | — | ↗ |
| 2022-08-24 | LOWE CHRISTOPHER P. | Director | P-Purchase | A | Common Stock | 18,400 | 1.65 | 30.3K | 28,400 | — | ↗ |
| 2022-06-27 | Izumi Raquel E. | Officer | P-Purchase | A | Common Stock | 40,000 | 1.41 | 56.3K | 40,000 | — | ↗ |
| 2022-06-23 | Hamdy Ahmed MD | Officer | P-Purchase | A | Common Stock | 24,200 | 1.41 | 34.1K | 38,480 | — | ↗ |
| 2022-06-09 | Bushnell Laura I. | Director | P-Purchase | A | Common Stock | 15,000 | 1.91 | 28.6K | 19,202 | — | ↗ |
| 2022-05-26 | Stevens Ruth E. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-26 | Salva Francisco D. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-26 | McDonald Andrew I | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-26 | Lee John H. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.61 | 24.2K | 15,000 | — | ↗ |
| 2022-05-26 | LOWE CHRISTOPHER P. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 1.61 | 24.2K | 15,000 | — | ↗ |
| 2022-05-26 | Druker Brian | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-26 | Bushnell Laura I. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-02-14 | Zhang Xiaoming | Officer | A-Award | A | Stock Option (right to buy) | 34,000 | 6.26 | 212.8K | 34,000 | — | ↗ |
| 2022-02-14 | THOMAS TOM C | Officer | A-Award | A | Stock Option (right to buy) | 55,250 | 6.26 | 345.9K | 55,250 | — | ↗ |
| 2022-02-14 | Seelenberger Alexander A. | Officer | A-Award | A | Stock Option (right to buy) | 55,250 | 6.26 | 345.9K | 55,250 | — | ↗ |
| 2022-02-14 | Izumi Raquel E. | Director / Officer | A-Award | A | Stock Option (right to buy) | 76,500 | 6.26 | 478.9K | 76,500 | — | ↗ |
| 2022-02-14 | Hwang Sooin | Officer | A-Award | A | Stock Option (right to buy) | 34,000 | 6.26 | 212.8K | 34,000 | — | ↗ |
| 2022-02-14 | Hamdy Ahmed MD | Director / Officer | A-Award | A | Stock Option (right to buy) | 127,500 | 6.26 | 798.2K | 127,500 | — | ↗ |
| 2022-02-14 | Garban Hermes de Jesus | Officer | A-Award | A | Stock Option (right to buy) | 55,250 | 6.26 | 345.9K | 55,250 | — | ↗ |
| 2022-01-20 | Rubric Capital Management LP | 10% Owner | — | I | Common stock, par value $0.0001 per share | 0 | 0.00 | — | 2,107,000 | — | ↗ |
| 2021-12-23 | Hwang Sooin | Officer | P-Purchase | A | Common Stock | 3,000 | 10.00 | 30.0K | 390,491 | — | ↗ |
| 2021-12-22 | THOMAS TOM C | Officer | P-Purchase | A | Common Stock | 1,000 | 10.23 | 10.2K | 3,000 | — | ↗ |
| 2021-12-22 | Seelenberger Alexander A. | Officer | P-Purchase | A | Common Stock | 2,417 | 10.34 | 25.0K | 12,493 | — | ↗ |
| 2021-12-22 | Hamdy Ahmed MD | Director / Officer | P-Purchase | A | Common Stock | 6,450 | 10.02 | 64.6K | 14,280 | — | ↗ |
| 2021-12-22 | Bushnell Laura I. | Director | P-Purchase | A | Common Stock | 2,402 | 10.48 | 25.2K | 4,202 | — | ↗ |
| 2021-08-12 | Zhang Xiaoming | Officer | — | D | Stock Option (right to buy) | 150,000 | 19.00 | 2.85M | 0 | — | ↗ |
| 2021-08-04 | Izumi Raquel E. | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 11.96 | 12.0K | 1,000 | — | ↗ |
| 2021-06-30 | LOWE CHRISTOPHER P. | Director | P-Purchase | A | Common Stock | 3,600 | 12.66 | 45.6K | 10,000 | — | ↗ |
| 2021-06-30 | Hwang Sooin | Officer | P-Purchase | A | Common Stock | 500 | 12.66 | 6.3K | 385,575 | — | ↗ |
| 2021-06-30 | Bushnell Laura I. | Director | P-Purchase | A | Common Stock | 1,800 | 12.94 | 23.3K | 1,800 | — | ↗ |
| 2021-06-29 | THOMAS TOM C | Officer | P-Purchase | A | Common Stock | 2,000 | 12.58 | 25.2K | 2,000 | — | ↗ |
| 2021-06-29 | Seelenberger Alexander A. | Officer | P-Purchase | A | Common Stock | 7,950 | 12.61 | 100.3K | 7,950 | — | ↗ |
| 2021-06-29 | McDonald Andrew I | Director | P-Purchase | A | Common Stock | 20,000 | 12.38 | 247.6K | 20,000 | — | ↗ |
| 2021-06-29 | Lee John H. | Director | P-Purchase | A | Common Stock | 799 | 12.72 | 10.2K | 799 | — | ↗ |
| 2021-06-29 | LOWE CHRISTOPHER P. | Director | P-Purchase | A | Common Stock | 6,400 | 12.59 | 80.6K | 6,400 | — | ↗ |
| 2021-06-29 | Hamdy Ahmed MD | Director / Officer | P-Purchase | A | Common Stock | 7,830 | 12.77 | 100.0K | 7,830 | — | ↗ |
| 2021-05-13 | Stevens Ruth E. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 16.34 | 326.8K | 20,000 | — | ↗ |
| 2021-05-13 | Salva Francisco D. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 16.34 | 326.8K | 20,000 | — | ↗ |
| 2021-05-13 | McDonald Andrew I | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 20,000 | 16.34 | 326.8K | 20,000 | — | ↗ |
| 2021-05-13 | Lee John H. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 16.34 | 326.8K | 20,000 | — | ↗ |
| 2021-05-13 | LOWE CHRISTOPHER P. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 16.34 | 326.8K | 20,000 | — | ↗ |
| 2021-05-13 | Hwang Sooin | Officer | — | D | Common Stock | 0 | 0.00 | — | 385,075 | — | ↗ |
| 2021-05-13 | Druker Brian | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 16.34 | 326.8K | 20,000 | — | ↗ |
| 2021-05-13 | Bushnell Laura I. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 16.34 | 326.8K | 20,000 | — | ↗ |
| 2021-03-15 | THOMAS TOM C | Officer | — | D | Common Stock | 0 | 0.00 | — | 205,522 | — | ↗ |
| 2021-03-01 | Garban Hermes de Jesus | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 19.24 | 2.89M | 150,000 | — | ↗ |
| 2021-01-28 | McDonald Andrew I | Director | J-Other | A | Common Stock | 808,471 | 0.00 | — | 808,471 | — | ↗ |
| 2020-12-23 | Seelenberger Alexander A. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-23 | Salva Francisco D. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-23 | McDonald Andrew I | Director | A-Award | A | Stock Option (right to buy) | 6,667 | 19.00 | 126.7K | 6,667 | — | ↗ |
| 2020-12-23 | McCamish Mark Anthony | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-23 | Lee John H. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-23 | LOWE CHRISTOPHER P. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-23 | Izumi Raquel E. | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-23 | Hamdy Ahmed MD | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-23 | Druker Brian | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-23 | Byrd John C. | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-23 | Bushnell Laura I. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-03-10 | Rice Michael Yehuda | Director / Officer / 10% Owner | A-Award | A | Warrants | 1,570,000 | 11.50 | 18.06M | 1,570,000 | — | ↗ |
| 2020-03-10 | McDonald Andrew I | Director / Officer / 10% Owner | A-Award | A | Warrants | 1,570,000 | 11.50 | 18.06M | 1,570,000 | — | ↗ |
| 2020-03-10 | Dobkin David | Director / Officer | A-Award | A | Warrants | 1,570,000 | 11.50 | 18.06M | 1,570,000 | — | ↗ |
| 2020-03-05 | Ziegler John Steven | Director | — | D | Common Stock | 0 | 0.00 | — | 6,000 | — | ↗ |
| 2020-03-05 | Walker Karin L | Director | — | D | Common Stock | 0 | 0.00 | — | 6,000 | — | ↗ |
| 2020-03-05 | SCHWARTZ BRIAN | Director | — | D | Common Stock | 0 | 0.00 | — | 6,000 | — | ↗ |
| 2020-03-05 | Rice Michael Yehuda | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,701,000 | — | ↗ |
| 2020-03-05 | Rice Michael | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,701,000 | — | ↗ |
| 2020-03-05 | McDonald Andrew I | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,701,000 | — | ↗ |
| 2020-03-05 | LifeSci Investments, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,701,000 | — | ↗ |
| 2020-03-05 | Dobkin David | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-03-05 | Dennis Barry | Director | — | D | Common Stock | 0 | 0.00 | — | 6,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
5.23M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Ahmed M. Hamdy, M.D. Chief Executive Officer | 479.2K | 164.8K | — | 77.4K | — | 13.5K | 735.0K | 10.53% | ↗ |
| 2 | 2023 | Raquel E. Izumi, Ph.D. President and Chief Operations Officer | 447.9K | 132.1K | — | 77.4K | — | 11.6K | 669.0K | 11.57% | ↗ |
| 3 | 2023 | Alexander A. Seelenberger Chief Financial Officer | 369.8K | 109.0K | — | 74.0K | — | 12.9K | 565.7K | 13.08% | ↗ |
| 4 | 2022 | Ahmed M. Hamdy, M.D. Chief Executive Officer | 460.0K | 136.9K | — | 670.1K | — | 13.0K | 1.28M | 52.35% | ↗ |
| 5 | 2022 | Raquel E. Izumi, Ph.D. President and Chief Operations Officer | 430.0K | 109.7K | — | 445.2K | — | 12.0K | 996.9K | 44.66% | ↗ |
| 6 | 2022 | Alexander A. Seelenberger Chief Financial Officer | 355.0K | 90.5K | — | 346.7K | — | 12.5K | 804.7K | 43.08% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2025-07-16 | DEFA14A | ↗ |
| 2025-07-07 | DEFA14A | ↗ |
| 2025-06-18 | DEFA14A | ↗ |
| 2025-06-06 | DEFA14A | ↗ |
| 2025-05-12 | DEF 14A | ↗ |
| 2025-04-30 | PRE 14A | ↗ |
| 2025-02-06 | DEFA14A | ↗ |
| 2025-01-29 | DEFA14A | ↗ |
| 2025-01-23 | DEFA14A | ↗ |
| 2024-12-10 | DEF 14A | ↗ |
| 2024-11-05 | PRE 14A | ↗ |
| 2024-08-02 | DEFA14A | ↗ |
| 2024-07-08 | DEF 14A | ↗ |
| 2024-06-28 | PRE 14A | ↗ |
| 2024-04-10 | DEFA14A | ↗ |
| 2024-04-10 | DEF 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Raquel E. Izumi | Co-Founder, Acting Chief Executive Officer, Secretary & Director | 1M | — |
| Alexander A. Seelenberger | Consultant | 854.3K | male |
| Tom C. Thomas | Consultant | 854.3K | male |
| Hans-Georg Lerchen | Chief Scientific Officer | — | — |
| John C. Byrd | Founder & Chairman of Scientific Advisory Board | — | — |
| Karen Quarford | Vice President of Quality Operations & Compliance | — | female |
| Kevin Haas | Acting Chief Financial Officer, Vice President of Finance & Corporate Controller | — | male |
| Melissa Merrick SPHR | Senior Director of People & Culture and Head of Human Resource | — | female |
| Beatrix Stelte-Ludwig | Executive Chief Development Officer | — | — |
| Gabriela Jairala | Vice President of Investor Relations & Corporate Communications and Chief of Staff | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VINC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
